Allogene Therapeutics ALLO Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $150.15M-21.9% | $192.3M-20.8% | $242.91M-5.3% | $256.39M+16.4% | ||
| $56.78M-12.9% | $65.21M-9.0% | $71.67M-9.6% | $79.31M+7.0% | ||
| $209.32M-23.4% | $273.22M-16.7% | $327.83M-2.3% | $335.69M+14.1% | ||
| -$209.32M+23.4% | -$273.2M+16.6% | -$327.74M+2.3% | -$335.54M-84.5% | ||
| $1.08M+494% | $181K— | $0— | —— | ||
| $19.29M-4.3% | $20.15M+10.1% | $18.31M+301% | $4.57M+166% | ||
| $18.43M+14.8% | $16.05M— | —— | -$4.88M-163% | ||
| -$190.89M+25.9% | -$257.59M+21.3% | -$327.27M+3.9% | -$340.41M-86.9% | ||
| -$0.87+34.6% | -$1.33+37.0% | -$2.11+11.7% | -$2.39-77.0% | ||
| -$0.87+34.6% | -$1.33+37.0% | -$2.11+11.7% | -$2.39-77.0% | ||
| 876.9M+14.9% | 763.2M+23.9% | 615.9M+7.8% | 571.6M+5.9% | ||
| 876.9M+14.9% | 763.2M+23.9% | 615.9M+7.8% | 571.6M+5.9% | ||
| -$190.53M+25.8% | -$256.72M+19.3% | -$318.29M+8.5% | -$347.77M-88.1% | ||
| $19.29M-4.3% | $20.15M+10.1% | $18.31M+301% | $4.57M+166% | ||
| $358K— | —— | $8.97M— | —— | ||
| $215K+105% | -$3.92M+69.5% | -$12.84M-36.0% | -$9.44M-245% | ||
| -$209.32M+23.4% | -$273.2M+16.6% | -$327.74M+2.3% | -$335.54M-84.5% | ||
| -$196.96M+24.1% | -$259.56M+17.2% | -$313.54M+2.4% | -$321.24M-87.4% | ||
| -$196.96M+24.1% | -$259.56M+17.2% | -$313.54M+2.4% | -$321.24M-87.4% | ||
| -$209.32M+23.4% | -$273.2M+16.6% | -$327.74M+2.3% | -$335.54M-84.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Allogene Therapeutics profitable?
- Allogene Therapeutics is not currently profitable: it reported a net loss of $173.8M over the trailing twelve months, a -1170863.6% net margin.
- What is Allogene Therapeutics's earnings per share?
- Allogene Therapeutics's diluted EPS over the trailing twelve months is $-0.77.
- Where does Allogene Therapeutics's income statement data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.